<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574245</url>
  </required_header>
  <id_info>
    <org_study_id>S2020-381</org_study_id>
    <nct_id>NCT04574245</nct_id>
  </id_info>
  <brief_title>Gastric Cancer Liver Metastasis Cohort of China</brief_title>
  <acronym>RECORD</acronym>
  <official_title>Retrospective Multi-institutional Cohort Study of Gastric Cancer Liver Metastasis in Real-world Data of China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-institutional retrospective cohort study aimed to describe and analyze the overall&#xD;
      clinical characteristics, therapeutic status and prognosis pattern of gastric cancer liver&#xD;
      metastasis (GCLM) in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>2011/01/01-2020/12/31</time_frame>
    <description>The proportion (%) of gastric cancer liver metastasis patients that survived beyond one-year follow-up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>2011/01/01-2021/12/31</time_frame>
    <description>The proportion (%) of gastric cancer liver metastasis patients that survived beyond three-year follow-up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>2011/01/01-2021/12/31</time_frame>
    <description>The proportion (%) of gastric cancer liver metastasis patients that survived beyond five-year follow-up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of gastric cancer liver metastasis cases</measure>
    <time_frame>2010/01/01-2019/12/31</time_frame>
    <description>The rate of gastric cancer liver metastasis cases divided by all gastric cancer cases in the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion for synchronous and metachronous liver metastases cases</measure>
    <time_frame>2010/01/01-2019/12/31</time_frame>
    <description>The proportion (%) of synchronous or metachronous gastric cancer liver metastases cases in all gastric cancer cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The survival of patients that recieved different therapeutic methods</measure>
    <time_frame>2010/01/01-2019/12/31</time_frame>
    <description>The proportion (%) of patients under different therapies that survived beyond specific follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prognostic predictive value for patients with different C-GCLM classification</measure>
    <time_frame>2010/01/01-2019/12/31</time_frame>
    <description>The proportion (%) of patients of different classification that survived beyond specific follow-up period.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Resectable group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Potentially resectable group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Unresectable group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy; Hepatectomy</intervention_name>
    <arm_group_label>Resectable group</arm_group_label>
    <other_name>Radiofrequency ablation</other_name>
    <other_name>Chemotherapy</other_name>
    <other_name>Immunotherapy</other_name>
    <other_name>Target therapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible in-hospital gastric cancer liver metastases cases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gastric cancer liver metastases cases aged over 18 years old;&#xD;
&#xD;
          -  Primary gastric carcinoma (including different histopathological types) confirmed by&#xD;
             biopsy or surgery (pre-, intra- or post- treatment);&#xD;
&#xD;
          -  In hospital cases between 2020/01/01 to 2019/12/3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor compliance to treatment or lost to follow-up;&#xD;
&#xD;
          -  Gross loss of clinical data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunhe Gao, Ph.D.</last_name>
    <phone>86-18310858130</phone>
    <email>yunhe_gao301@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiuxia Cui, Ph.D.</last_name>
    <phone>86-15171431829</phone>
    <email>cherishcqx@sina.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Surgery Institute, China PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunhe Gao, Ph.D.</last_name>
      <phone>86-010-66937164</phone>
      <email>gaoyunhe@301hospital.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang K, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. Ther Adv Med Oncol. 2020 Feb 20;12:1758835920904803. doi: 10.1177/1758835920904803. eCollection 2020.</citation>
    <PMID>32127925</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lin Chen</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Prognosis</keyword>
  <keyword>Multidisciplinary treatment</keyword>
  <keyword>C-GCLM Classification</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Liver metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

